Inclisiran for Cardiovascular Disease Prevention

"The safety of Inclisiran Sodium 300mg was deemed satisfactory, garnering a score of 3. This is due to the existing body of evidence proving its efficacy and multiple studies affirming its security parameters."

"According to the inclusion criteria, only individuals aged between 40 and 79 may enrol in this trial. There are 31 studies conducted on persons under 18 years old, as well as 463 for those who exceed 65."

"According to the information advertised on clinicaltrials.gov, this trial is actively recruiting participants. The original post was made on March 9th 2023 while its most recent update occurred on 23rd of the same month."

"Indeed, the clinicaltrials.gov database shows that this trial is still enrolling participants. The research first appeared on March 9th 2023 and was last updated two weeks later on March 23rd 2023. In total, 14000 patients are being sought from 8 different sites."

"8 medical centres in the United States are currently enrolling patients, including Covington, Zachary and Amarillo. To minimise travel expenses related to participation in this study it is advised that you select the closest site to your location."

"This clinical trial seeks to enrol 14,000 patients aged 40-79 with the purpose of preventing atherosclerotic cardiovascular disease. The contenders must meet a few criteria such as having a stable dose of lipid-lowering medication for 4 weeks before screening and an LDL cholesterol concentration between 70 mg/dL (1.81 mmol/L) and 190 mg/dL (4.91 mmol/L). Furthermore, they should have either coronary artery calcium score ≥100 Agatston units or evidence of CAD on CT scan representing stenosis 20%-50% in left main coronary artery & 20%-70% any major epicardial vessel"